$16.6 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 136 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANTM | ANTHEM INC | $409,390,000 | +19.5% | 1,275,000 | 0.0% | 2.46% | +3.9% | |
| XLRN | ACCELERON PHARMA INC | $332,644,000 | +13.7% | 2,600,000 | 0.0% | 2.00% | -1.1% | |
| TIF | TIFFANY & CO NEW | $300,626,000 | +13.5% | 2,287,000 | 0.0% | 1.81% | -1.4% | |
| MRTX | MIRATI THERAPEUTICS INC | $192,185,000 | +32.3% | 875,000 | 0.0% | 1.16% | +15.0% | |
| APLS | APELLIS PHARMACEUTICALS INC | $130,130,000 | +89.6% | 2,275,000 | 0.0% | 0.78% | +64.8% | |
| SRPT | SAREPTA THERAPEUTICS INC | $102,294,000 | +21.4% | 600,000 | 0.0% | 0.62% | +5.5% | |
| PCG | PG&E CORP | $90,859,000 | +32.7% | 7,292,042 | 0.0% | 0.55% | +15.2% | |
| SAGE | SAGE THERAPEUTICS INC | $90,836,000 | +41.5% | 1,050,000 | 0.0% | 0.55% | +23.0% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $74,728,000 | -8.0% | 1,775,000 | 0.0% | 0.45% | -20.1% | |
| BRMK | BROADMARK RLTY CAP INC | $73,136,000 | +3.4% | 7,170,213 | 0.0% | 0.44% | -10.0% | |
| KRTX | KARUNA THERAPEUTICS INC | $71,113,000 | +31.4% | 700,000 | 0.0% | 0.43% | +14.4% | |
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $53,806,000 | +8.0% | 56,695,000 | 0.0% | 0.32% | -6.1% | ||
| ZGNX | ZOGENIX INC | $44,978,000 | +11.5% | 2,250,000 | 0.0% | 0.27% | -2.9% | |
| RDUS | RADIUS HEALTH INC | $37,638,000 | +57.5% | 2,107,400 | 0.0% | 0.23% | +37.0% | |
| CLOVIS ONCOLOGY INCnote 1.250% 5/0 | $36,077,000 | -0.5% | 51,910,000 | 0.0% | 0.22% | -13.5% | ||
| LNTH | LANTHEUS HLDGS INC | $35,749,000 | +6.5% | 2,650,000 | 0.0% | 0.22% | -7.3% | |
| IQIYI INCnote 3.750%12/0 | $29,894,000 | -7.4% | 29,689,000 | 0.0% | 0.18% | -19.3% | ||
| ATENTO S A | $18,227,000 | +51.9% | 2,230,357 | 0.0% | 0.11% | +32.5% | ||
| PLRX | PLIANT THERAPEUTICS INC | $17,364,000 | +0.4% | 764,262 | 0.0% | 0.10% | -13.3% | |
| RC | READY CAPITAL CORP | $16,810,000 | +11.2% | 1,350,226 | 0.0% | 0.10% | -3.8% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $16,260,000 | +5.2% | 1,500,000 | 0.0% | 0.10% | -8.4% | |
| APELLIS PHARMACEUTICALS INCnote 3.500% 9/1 | $5,930,000 | +54.8% | 3,522,000 | 0.0% | 0.04% | +38.5% | ||
| RADIUS HEALTH INCnote 3.000% 9/0 | $5,995,000 | +9.5% | 6,783,000 | 0.0% | 0.04% | -5.3% | ||
| SVRA | SAVARA INC | $5,120,000 | +5.5% | 4,452,086 | 0.0% | 0.03% | -8.8% | |
| ISEE | IVERIC BIO INC | $5,215,000 | +22.5% | 754,740 | 0.0% | 0.03% | +6.9% | |
| EQ | EQUILLIUM INC | $3,745,000 | -7.3% | 700,000 | 0.0% | 0.02% | -17.9% | |
| BRMKWS | BROADMARK RLTY CAP INC*w exp 11/15/202 | $1,937,000 | -6.1% | 7,174,613 | 0.0% | 0.01% | -14.3% | |
| GOL | GOL LINHAS AEREAS INTELIGENTspon adr pfd new | $843,000 | +60.9% | 85,838 | 0.0% | 0.01% | +25.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.